Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1, ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to a potential multibillion ...

W estern drugmakers, including Eli Lilly , Pfizer , and Novo Nordisk , are looking to boost sales of their most innovative and expensive medicines in China, the world’s second-l ...

Six months into Donald Trump’s second term, his administration is at war with the federal judiciary, evading court orders ...

Patients on a combination of toripalimab and RemeGen's anti-HER2 antibody disitamab vedotin fared better than those on a chemotherapy regimen.

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

The dollar fell against a basket of currencies, after President Trump said he would nominate Stephen Miran to temporarily join the Federal Reserve's board of governors. "Miran has expressed skepticism ...

News of a trade secrets leak involving TSMC and an action in Japan against AI startup Perplexity were also among the top ...

Dow Jones Top Company Headlines at 5 AM ET: Intel's CEO, Under Attack From Trump, Is Already at Odds With His Board | Apple ... Intel's CEO, Under Attack From Trump, Is Already at Odds With His Board ...

Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.